Sodium tungstate promotes vascularization to support beta bell replacement in diabetes

Sodium tungstate enhances vascularization and survival of transplanted insulin-producing cells in diabetic models by inhibiting phosphatase activity to upregulate VEGFA and activate MAPK/ERK signaling, thereby improving graft integration and therapeutic efficacy without requiring exogenous endothelial supplementation.

The Gist

The Big Picture: The "Island" Problem

Imagine you are trying to build a new city (a cure for diabetes) by transplanting a group of hardworking citizens (insulin-producing cells) into a new neighborhood. These citizens are essential because they manage the city's energy supply (blood sugar).

However, there is a major problem: The neighborhood has no roads or water pipes.

When these new cells are transplanted into a patient, they are stranded on an island. Without a network of blood vessels (roads) to bring them oxygen and food, most of them die within days. This is the biggest hurdle in curing diabetes with cell transplants. The cells are there, but they are starving and suffocating before they can do their job.

The Solution: Sodium Tungstate (The "Super-Connector")

The researchers in this paper discovered a simple, safe chemical called Sodium Tungstate (let's call it "NaW" for short). Think of NaW as a universal construction foreman that does two amazing things at once to fix the "no roads" problem.

1. It Shouts for Help (The Signal)

First, NaW goes into the transplanted cells and tells them to start shouting for help. Specifically, it makes them produce more of a chemical signal called VEGFA.

• The Analogy: Imagine the stranded citizens start waving giant red flags. These flags are the VEGFA signal. They tell the body, "We are here! We need roads and water pipes immediately!"

2. It Speeds Up the Construction Crew (The Response)

Second, NaW doesn't just stop at shouting. It also goes directly to the body's construction crew (the blood vessel cells) and gives them a super-charged energy drink.

• The Analogy: When the construction crew sees the red flags, they usually start building slowly. But because NaW is also in the system, the crew starts building twice as fast. They multiply, they move quickly to the site, and they lay down new pipes (blood vessels) much faster than usual.

The Experiment: Testing the Theory

The scientists tested this on two different types of "citizens":

1. Reprogrammed Cells: Cells taken from human skin and turned into insulin-makers.
2. Stem Cell Islets: Cells grown in a lab from stem cells.

They transplanted these cells into mice (specifically into the eye, which is like a clear window to watch the construction happen in real-time).

The Results:

• Without NaW: The cells struggled. The roads were slow to build, and many cells died of starvation.
• With NaW: The "construction crew" arrived early and worked overtime. The grafts became connected to the body's blood supply twice as fast. Because the roads were built quickly, the cells survived, stayed healthy, and started producing insulin effectively.

Why This is a Big Deal

Usually, to fix this problem, scientists try to transplant the cells along with the construction crew (endothelial cells) already attached to them. But that is like trying to build a house while carrying the bricks and the workers in your pocket—it's messy, complicated, and hard to control.

NaW changes the game because it is a "magic potion" you can just give to the patient.

• It's Simple: You don't need to engineer complex cell mixtures. You just give the patient a drink containing NaW.
• It's Safe: This chemical has been used for years to treat diabetes and obesity in other studies and is known to be safe.
• It's Dual-Action: It helps the new cells survive and helps the body build the necessary support network simultaneously.

The Bottom Line

This paper suggests that by giving patients a simple, safe chemical (Sodium Tungstate) right after a cell transplant, we can stop the new cells from dying of starvation. It acts like a turbo-boost for the body's natural ability to build roads to the new cells, ensuring they survive, thrive, and cure the diabetes.

It turns a "stranded island" scenario into a "thriving city" scenario, potentially making cell-based cures for diabetes a reality for many more people.

Technical Summary

1. Problem Statement

Cell-based therapies for Type 1 Diabetes (T1D), utilizing either donor islets or stem cell-derived islets (SC-islets), face a critical bottleneck: insufficient and delayed graft vascularization.

• Consequences: Without rapid revascularization, transplanted cells suffer from hypoxia and nutrient deprivation, leading to high rates of cell death (50–70% loss) and poor long-term function.
• Current Limitations:
  • Isolation and culture processes disrupt existing intra-islet vasculature.
  • In vitro-generated islets (SC-islets) lack intrinsic vasculature entirely.
  • Encapsulation devices often block vascular integration.
  • Strategies like co-transplanting endothelial cells (ECs) or using VEGF overexpression have limitations regarding stability, immunogenicity, and the risk of excessive, disorganized angiogenesis.
• Hypothesis: The authors hypothesized that pharmacological inhibition of the phosphatase PTP1B using Sodium Tungstate (NaW) could replicate the beneficial vascularization effects previously observed in PTP1B-deficient mice, thereby improving graft survival and function without genetic manipulation.

2. Methodology

The study employed a multi-model approach combining in vitro mechanistic assays and in vivo transplantation models in immunodeficient mice.

• Cell Models:
  1. Human iBeta-like cells: Generated via direct reprogramming of human fibroblasts using five transcription factors (Neurog3, Pdx1, Mafa, Pax4, Nkx2.2).
  2. Human SC-islets: Differentiated from human embryonic stem cells (H1 line) using a clinically validated 7-stage protocol.
  3. Co-cultures: iBeta-like cells and SC-islets were aggregated with Human Umbilical Vein Endothelial Cells (HUVECs) at a 1:9 ratio to test the synergy of NaW with exogenous ECs.
• Transplantation Model:
  • Site: Anterior Chamber of the Eye (ACE) in NSG (NOD scid gamma) mice. This site allows for high-resolution in vivo imaging of graft vascularization.
  • Treatment: Mice received NaW (1 g/L) in drinking water post-transplantation.
  • Controls: Untreated mice or mice receiving vehicle.
• Assessment Techniques:
  • Functional Vascularization: In vivo two-photon microscopy using RITC-dextran (fluorescent blood tracer) to quantify vascularized area and vessel density at days 4, 10, 15, and 30.
  • Histology & Immunofluorescence: Quantification of insulin-positive (INS⁺) area, glucagon-positive (GCG⁺) area, cell death (TUNEL), proliferation (Ki67), and VEGFA expression.
  • In Vitro Mechanisms:
    • HUVEC viability (MTT), proliferation (cell counting), migration (wound healing), and tube formation assays.
    • Signaling analysis via Western Blot for MAPK/ERK phosphorylation.
    • VEGFA quantification (mRNA and protein) in iBeta-like cells under normoxic and hypoxic conditions.

3. Key Contributions

• Pharmacological Reprogramming: Demonstrated that a small molecule (NaW), known for its safety profile and oral bioavailability, can effectively enhance graft vascularization, offering a clinically translatable alternative to genetic modification or complex cell co-cultures.
• Dual-Mechanism Discovery: Identified that NaW acts via a dual mechanism:
  1. Endocrine Side: Upregulates VEGFA production in transplanted beta-like cells.
  2. Endothelial Side: Potentiates VEGFA-induced signaling (MAPK/ERK pathway) in host endothelial cells, enhancing their proliferation, migration, and tubulogenesis.
• Independence from Exogenous ECs: Showed that NaW significantly improves vascularization and graft survival in SC-islet grafts without the need to co-transplant exogenous endothelial cells, relying instead on recruiting host endogenous vasculature.

4. Key Results

A. Vascularization and Graft Survival

• NaW + iBeta-like/HUVEC Grafts:
  • Vascularization: NaW treatment doubled the vascularized area and increased vessel density by 50% compared to controls at day 10.
  • Cell Survival: Reduced apoptosis in the non-endothelial (HLA⁺CD34⁻) compartment.
  • Beta Cell Mass: Increased the proportion of INS⁺ cells by ~50% at day 10 and maintained a two-fold increase in total INS⁺ cell numbers at day 30.
  • Mechanism: NaW treatment increased the percentage of INS⁺ cells co-expressing VEGFA (from 43% to 69%) at day 10. This effect was transient, normalizing by day 30.
• NaW + SC-islet Grafts:
  • Vascularization: NaW significantly increased vascularized area and vessel density at days 15 and 30.
  • Source of Vessels: Immunostaining confirmed that new vessels were derived exclusively from host (mouse) endothelial cells, not the transplanted human cells.
  • Graft Function: NaW-treated grafts showed a two-fold increase in INS⁺ area and significantly higher circulating human insulin levels at day 30.
  • Apoptosis: Marked reduction in INS⁺ cell death at day 15.

B. In Vitro Mechanistic Insights

• VEGFA Production: NaW directly increased VEGFA mRNA and protein secretion in iBeta-like cells, an effect amplified under hypoxic conditions (mimicking the transplant microenvironment).
• Endothelial Response:
  • NaW alone had minimal effect on HUVEC proliferation but significantly enhanced VEGFA-driven proliferation, migration, and tube formation.
  • Signaling: NaW potentiated VEGFA-induced phosphorylation of ERK1/2 (MAPK pathway), suggesting it acts by inhibiting PTP1B-mediated dephosphorylation of VEGFR2, thereby sustaining downstream angiogenic signaling.

C. Interaction with Exogenous Endothelial Cells

• In SC-islet grafts containing HUVECs, NaW increased vessel density but did not further improve beta-cell mass or function compared to NaW-treated SC-islets without HUVECs.
• Interpretation: This suggests that beyond a certain threshold, additional vascular density (provided by HUVECs) does not linearly translate to better function, and NaW's ability to recruit host vessels is sufficient and potentially more efficient.

5. Significance and Conclusion

• Clinical Translation: Sodium Tungstate is an "off-the-shelf," orally bioavailable drug with a well-established safety profile in humans (previously tested for diabetes and fertility). This study positions it as a low-cost, scalable adjunct therapy to improve the success rate of beta-cell replacement trials.
• Paradigm Shift: The findings suggest that enhancing the host's vascular recruitment response via pharmacological modulation may be superior to complex strategies involving pre-vascularized grafts or exogenous EC co-transplantation.
• Future Directions: The authors propose that transient NaW administration during the peri-transplantation window could be a standard protocol to overcome the "vascularization lag" that currently limits the efficacy of cell-based diabetes therapies. Further studies are needed to validate these effects in subcutaneous or omental sites (more clinically relevant than the eye) and to assess long-term metabolic control in diabetic models.

In summary, the paper provides robust evidence that Sodium Tungstate acts as a potent pro-angiogenic adjuvant by simultaneously boosting VEGFA production in grafts and sensitizing host endothelial cells to angiogenic signals, thereby significantly improving the survival and function of transplanted insulin-producing cells.